.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
US Department of Justice
Federal Trade Commission
Boehringer Ingelheim
Chubb
Johnson and Johnson
Covington
Farmers Insurance
Merck
Julphar

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021436

« Back to Dashboard

NDA 021436 describes ABILIFY, which is a drug marketed by Otsuka and Otsuka Pharm Co Ltd and is included in five NDAs. It is available from fourteen suppliers. There are twenty-three patents protecting this drug and three Paragraph IV challenges. Additional details are available on the ABILIFY profile page.

The generic ingredient in ABILIFY is aripiprazole. There are forty-four drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.

Summary for 021436

Tradename:1
Applicant:1
Ingredient:1
Patents:10
Therapeutic Class:Antipsychotics
Bipolar Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 021436

Medical Subject Heading (MeSH) Categories for 021436

Suppliers and Packaging for NDA: 021436

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ABILIFY aripiprazole TABLET;ORAL 021436 NDA STAT RX USA LLC 16590-323 16590-323-60 60 TABLET in 1 BOTTLE, PLASTIC (16590-323-60)
ABILIFY aripiprazole TABLET;ORAL 021436 NDA STAT RX USA LLC 16590-323 16590-323-30 30 TABLET in 1 BOTTLE, PLASTIC (16590-323-30)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength10MG
Approval Date:Nov 15, 2002TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Jun 9, 2017
Regulatory Exclusivity Use:LABELING REVISIONS RESULTING FROM A MAINTENANCE TRIAL IN PEDIATRIC PATIENTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
Regulatory Exclusivity Expiration:Dec 12, 2021
Regulatory Exclusivity Use:ORPHAN DRUG EXCLUSIVITY
Regulatory Exclusivity Expiration:Dec 12, 2017
Regulatory Exclusivity Use:TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S DISORDER (6-18 YEARS)

Expired Orange Book Patents for NDA: 021436

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
OtsukaABILIFYaripiprazoleTABLET;ORAL021436-003Nov 15, 2002► Subscribe► Subscribe
OtsukaABILIFYaripiprazoleTABLET;ORAL021436-006Nov 15, 2002► Subscribe► Subscribe
OtsukaABILIFYaripiprazoleTABLET;ORAL021436-002Nov 15, 2002► Subscribe► Subscribe
OtsukaABILIFYaripiprazoleTABLET;ORAL021436-005Nov 15, 2002► Subscribe► Subscribe
OtsukaABILIFYaripiprazoleTABLET;ORAL021436-002Nov 15, 2002► Subscribe► Subscribe
OtsukaABILIFYaripiprazoleTABLET;ORAL021436-003Nov 15, 2002► Subscribe► Subscribe
OtsukaABILIFYaripiprazoleTABLET;ORAL021436-004Nov 15, 2002► Subscribe► Subscribe
OtsukaABILIFYaripiprazoleTABLET;ORAL021436-004Nov 15, 2002► Subscribe► Subscribe
OtsukaABILIFYaripiprazoleTABLET;ORAL021436-005Nov 15, 2002► Subscribe► Subscribe
OtsukaABILIFYaripiprazoleTABLET;ORAL021436-006Nov 15, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Harvard Business School
Moodys
Novartis
US Department of Justice
Merck
Covington
Fish and Richardson
Medtronic
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot